Mainz Biomed N.V. (MYNZ) announced a strategic partnership with Quest Diagnostics Inc. (DGX) to introduce their NextGen-ColoAlert, an advanced colorectal cancer screening test, to the market. This stool-based diagnostic tool leverages polymerase chain reaction (PCR) technology to detect DNA markers specific to colorectal cancer, facilitating early-stage cancer detection.
Under the terms of the agreement, Quest will deliver clinical trial laboratory services to support Mainz Biomed's ReconAAsense study. Moreover, Mainz Biomed grants Quest an option to obtain semi-exclusive rights to offer testing services using the ColoAlert test kit for a period of 18 months, contingent upon FDA approval, as stated by the company.
On the Nasdaq, Mainz's stock is currently up by 26.42 percent, trading at $4.78.
The material has been provided by InstaForex Company - www.instaforex.com
Under the terms of the agreement, Quest will deliver clinical trial laboratory services to support Mainz Biomed's ReconAAsense study. Moreover, Mainz Biomed grants Quest an option to obtain semi-exclusive rights to offer testing services using the ColoAlert test kit for a period of 18 months, contingent upon FDA approval, as stated by the company.
On the Nasdaq, Mainz's stock is currently up by 26.42 percent, trading at $4.78.
The material has been provided by InstaForex Company - www.instaforex.com